Zephyrus Biosciences, Inc., a Berkeley, CA-based life science research tools company, secured $1.86m in seed funding.
The round was led by Life Sciences Angels, with participation from Mission Bay Capital, The Angel Forum, and the Stanford StartX Fund, as well investors with deep life sciences experience.
The company intends to use the funds to develop and commercialize its single cell Western blotting (scWestern) system to enable researchers to analyze proteins in thousands of single cells.
Co-founded by Drs. Kelly Gardner, Josh Molho, and Amy Herr, Zephyrus Biosciences provides tools to enable protein analysis at the single cell level. Its first product enables western blotting on individual cells for the first time. Based on over five years of research in Professor Amy Herr’s laboratory at the University of California, Berkeley, the technology promises to enable advances in diseases like cancer where understanding heterogeneity in cell populations is critical.
The company is affiliated with QB3, BayBio, StartX Med, a Stanford-affiliated nonprofit technology accelerator, and Berkeley Skydeck, an accelerator at U.C. Berkeley. In addition to the seed funding, Zephyrus Biosciences has been awarded a $350k Phase I SBIR grant from NIH and accessed $10k from the U.C. Bakar Fellows Program.